Comparative Pharmacology
Head-to-head clinical analysis: AZOPT versus NEPTAZANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZOPT versus NEPTAZANE.
AZOPT vs NEPTAZANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.
Methazolamide is a carbonic anhydrase inhibitor. It decreases intraocular pressure by inhibiting carbonic anhydrase in the ciliary epithelium, reducing aqueous humor secretion. It also has weak diuretic effects due to renal carbonic anhydrase inhibition.
One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.
50 mg orally twice daily, increasing to 50 mg three times daily if needed. Maximum dose: 200 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 111 minutes (1.85 hours) in plasma after topical ocular administration; prolonged in renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life: 8-12 hours. In renal impairment, half-life may extend to 20-30 hours, requiring dose adjustment.
Primarily renal excretion as unchanged drug (approximately 70% of a topically applied dose is absorbed systemically and excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Renal: 100% as unchanged drug via tubular secretion. No biliary or fecal elimination.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor